Longitudinal studies that continuously generate data enable the capture of temporal variations in experimentally observed parameters, facilitating the interpretation of results in a time-aware manner. We propose IL-VIS (incrementally learned visualizer), a new machine learning pipeline that incrementally learns and visualizes a progression trajectory representing the longitudinal changes in longitudinal studies. At each sampling time point in an experiment, IL-VIS generates a snapshot of the longitudinal process on the data observed thus far, a new feature that is beyond the reach of classical static models. We first verify the utility and correctness of IL-VIS using simulated data, for which the true progression trajectories are known. We find that it accurately captures and visualizes the trends and (dis)similarities between high-dimensional progression trajectories. We then apply IL-VIS to longitudinal multi-electrode array data from brain cortical organoids when exposed to different levels of quinolinic acid, a metabolite contributing to many neuroinflammatory diseases including Alzheimer's disease, and its blocking antibody. We uncover valuable insights into the organoids' electrophysiological maturation and response patterns over time under these conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169470 | PMC |
http://dx.doi.org/10.1038/s41598-024-63511-z | DOI Listing |
Sensors (Basel)
January 2025
African Centre of Excellence for Internet of Things, University of Rwanda, Kigali P.O. Box 4285, Rwanda.
The Internet of Things (IoT) and Industrial Internet of Things (IIoT) have drastically transformed industries by enhancing efficiency and flexibility but have also introduced substantial cybersecurity risks. The rise of zero-day attacks, which exploit unknown vulnerabilities, poses significant threats to these interconnected systems. Traditional signature-based intrusion detection systems (IDSs) are insufficient for detecting such attacks due to their reliance on pre-defined attack signatures.
View Article and Find Full Text PDFSensors (Basel)
December 2024
School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, UK.
Accurate depth estimation is crucial for many fields, including robotics, navigation, and medical imaging. However, conventional depth sensors often produce low-resolution (LR) depth maps, making detailed scene perception challenging. To address this, enhancing LR depth maps to high-resolution (HR) ones has become essential, guided by HR-structured inputs like RGB or grayscale images.
View Article and Find Full Text PDFJ Am Heart Assoc
January 2025
Department of Cardiology Beijing Anzhen Hospital, Capital Medical University Beijing China.
Background: Data on the predictive value of coronary computed tomography angiography-derived fractional flow reserve (CT-FFR) for long-term outcomes are limited.
Methods And Results: A retrospective pooled analysis of individual patient data was performed. Deep-learning-based CT-FFR was calculated.
Prev Sci
January 2025
School of Behavioral Health Sciences, The University of Texas Health Science Center at Houston, 7000 Fannin St, Houston, TX, 77030, USA.
Developing accurate and equitable screening protocols can lead to more targeted, efficient, and effective, teen dating violence (TDV) prevention programming. Current TDV screening protocols perform poorly and are rarely implemented, but recent research and policy emphasizes the importance of leveraging more trauma-focused screening measures for improved prevention outcomes. In response, the present study examined which adversities (i.
View Article and Find Full Text PDFNat Med
January 2025
Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia.
Neoadjuvant immunotherapies have shown antitumor activity in melanoma. Substudy 02C of the global, rolling-arm, phase 1/2, adaptive-design KEYMAKER-U02 trial is evaluating neoadjuvant pembrolizumab (anti-PD-1) alone or in combination, followed by adjuvant pembrolizumab, for stage IIIB-D melanoma. Here we report results from the first three arms: pembrolizumab plus vibostolimab (anti-TIGIT), pembrolizumab plus gebasaxturev (coxsackievirus A21) and pembrolizumab monotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!